TNFSF10 and glioblastoma: The activation of the extrinsic apoptotic pathways through DR4 and DR5 ligand-activation promotes the expression of various apoptosis inhibitory proteins in CSCs that include the NF-κB, which also makes CSCs resistant to TRAIL-based therapy, as seen in glioblastoma [154].